SynthoPlate: Nanotechnology for Intravenous Hemostasis and Wound Healing in Prolonged Field Care
Abstract
We have created a lipid-peptide conjugate based synthetic platelet technology (SynthoPlate (trademark), US 9107845, TRL 4), that mimics the inherent platelet-mediated mechanisms of primary and secondary hemostasis in a bleeding site selective fashion, without presenting potential systemic risks. In the current project, we seek to evaluate the point-of-care hemostatic efficacy and spatio-temporally targeted wound healing treatment applicability of the SynthoPlate (trademark) nanotechnology in appropriate porcine models, with a vision to translate this technology for prolonged combat casualty care in a far forward setting. Our specific aims are: Characterization of biodistribution, systemic risks and immune response of intravenously administered SynthoPlate (trademark) in pigs; Evaluation of hemostatic efficacy of pristine SynthoPlate (trademark) and TXA-loaded SynthoPlate (trademark) in a pig model of polytrauma; and Evaluate the efficacy of SynthoPlate (trademark) alone or in combination with Gentamicin to provide wound protection and improve re-epithelialization in porcine wound models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2023
- Accession Number
- AD1216829
Entities
People
- Anirban S. Gupta
- Matthew D Neal
- Rodney K Chan
Organizations
- Case Western Reserve University
- United States Army Institute of Surgical Research
- University of Pittsburgh